Quarterly Reports, License Applications, and Abstract Presentations - Research on Elan, NPS, ICON, Keryx, and Healthways

Quarterly Reports, License Applications, and Abstract Presentations - Research
                  on Elan, NPS, ICON, Keryx, and Healthways

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 29, 2013

NEW YORK, October 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Elan
Corporation, plc (NYSE: ELN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), ICON
Public Limited Company (NASDAQ: ICLR), Keryx Biopharmaceuticals Inc. (NASDAQ:
KERX), and Healthways, Inc. (NASDAQ: HWAY). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Elan Corporation, plc Research Report

On October 24, 2013, Elan Corporation, plc (Elan) released its Q3 2013
results. Elan registered revenues from continuing operations of $48.6 million
in Q3 2013, primarily attributable to $48.1 million royalty of 12% of global
net sales of Tysabri for Q3 2013. The Company posted net loss from continuing
operations of $13.8 million in Q3 2013, compared to a net loss from continuing
operations of $299.3 million in Q3 2012. Basic and diluted loss per share from
continuing operations was $0.03 in Q3 2013, compared to $0.51 in Q3 2012. The
Full Research Report on Elan Corporation, plc - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e996_ELN]

NPS Pharmaceuticals, Inc. Research Report

On October 24, 2013, NPS Pharmaceuticals, Inc. (NPS) announced the submission
of a Biologic License Application (BLA) to the US Food and Drug Administration
(FDA) for Natpara (recombinant human parathyroid hormone 1-84, rhPTH (1-84)).
According to NPS, Natpara is a bioengineered replacement for endogenous
parathyroid hormone (PTH) that NPS has developed for the treatment of
hypoparathyroidism, a rare endocrine disorder in which the body produces
insufficient levels of parathyroid hormone, a principal regulatory of the
body's mineral homeostasis. Francois Nader, MD, President and CEO of NPS,
stated, "Submitting our BLA for Natpara is a significant step forward for NPS
in our effort to bring the first replacement therapy to patients with
hypoparathyroidism." Nader continued, "Hypoparathyroidism patients face a
significant burden of disease given the multitude of physical, cognitive, and
emotional symptoms associated with this disorder." The Full Research Report on
NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/441a_NPSP]

ICON plc Research Report

On October 24, 2013, ICON plc (ICON) released its Q3 2013 results. ICON
registered net revenue of $339.8 million, up $19.0% YoY in Q3 2013. The
Company posted net income of $27.8 million, up 56.8% YoY in Q3 2013. ICON
reported diluted EPS of $0.45, up 55.2% YoY in Q3 2013. Ciaran Murray, CEO of
ICON, said, "For the quarter we are reporting revenue growth of 19% year on
year and operating margins of 9.8%. We booked $415 million of net new business
wins or a book to bill of 1.2, leaving us with a closing backlog of $2.97
billion. Consequently, we are raising our revenue guidance to the range of
$1.325 -$1.330 billion and our earnings per share guidance to the range of
$1.67-$1.70 for the financial year 2013." The Full Research Report on ICON plc
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/fbb0_ICLR]

Keryx Biopharmaceuticals Inc. Research Report

On October 17, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced that
abstracts highlighting Zerenex (ferric citrate coordination complex), the
Company's drug candidate for the treatment of elevated serum phosphorus
levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on
dialysis, have been selected for oral and poster presentations during the
American Society of Nephrology (ASN) Kidney Week 2013 annual meeting. Keryx
reported that the event will be held in Atlanta, Georgia from November 5 to
November 10, 2013. The Full Research Report on Keryx Biopharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/27d2_KERX]

Healthways, Inc. Research Report

On October 24, 2013, Healthways, Inc. (Healthways) released its Q3 2013
results. Healthways registered revenues of $166.6 million in Q3 2013, which
were flat as compared to Q3 2012. The Company reported net income of $1.8
million in Q3 2013, compared net income of $5.0 million in Q3 2012.
Healthways' diluted EPS was $0.05 in Q3 2013, compared to diluted EPS of $0.15
in Q3 2012. Ben R. Leedle, Jr., President and CEO at Healthways, commented,
"Healthways' financial results for the third quarter of 2013 were below our
expectations, and we are lowering our financial guidance for 2013 for two
primary reasons. The majority of the guidance change results from a much lower
number of risk lives available in 2013 for our total population management
services to health systems than was forecast in our previous guidance. A
smaller but still important impact came from the normal fluctuations in the
memberships of our commercial health plan customers, where we experienced a
net reduction in lives compared with our expectations." The Full Research
Report on Healthways, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/76fd_HWAY]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)